This product is a benzimidazole derivative, which is rapidly metabolized into sulfoxide, sulfone alcohol and 2-amine sulfone alcohol in the body. It selectively and irreversibly inhibits the polymerization of the cytoplasmic microtubule system of the parasite's intestinal wall cells, blocks its absorption of various nutrients and glucose, leads to the depletion of endogenous glycogen in the worm, and inhibits the fumarate reductase system, preventing the production of adenosine triphosphate, making it impossible for the worm to survive and reproduce. It can also cause the degeneration of the cytoplasmic microtubules of the worm's intestinal cells, and bind to its microtubule protein, causing intracellular transport blockage, resulting in the accumulation of Golgi endocrine granules, the gradual dissolution of the cytoplasm, and the complete degeneration of the absorbing cells, causing the death of the worm. It has the effect of completely killing hookworm eggs and whipworm eggs and partially killing ascarid eggs. In addition to killing and expelling various nematodes parasitic in animals, it also has a significant killing and expelling effect on tapeworms and cysticerci.

No specific pharmacological action is provided

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, but stronger than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the transfer of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, but stronger than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the transfer of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.